Three years after buying Bellus Health and its chronic cough candidate camlipixant for around $2 billion, GSK is abandoning ...

A federal judge in the US has sided with Amgen in a dispute over a price cap imposed by the state of Colorado on its blockbuster immunology drug Enbrel. In a move viewed as a test of states' ability ...

In the biggest venture capital financing this week, clinical-stage radiopharmaceutical AdvanCell has closed a $315 million ...

Mission Therapeutics of the UK has struck a deal to out-license a drug for acute kidney injury to Australia's Dimerix, ...

All 15-year-old children in the UK should be offered the vaccine against meningitis B (MenB) in the wake of fatal outbreaks ...

MSD has won the race to bring an oral PCSK9 inhibitor through to regulatory approval in the US, after getting the go-ahead ...

Though they are still primarily prescribed for weight loss and diabetes, researchers are looking at the effects of GLP-1s for a wide variety of conditions from substance abuse dis ...

For decades, pharmaceutical marketing has been built on a simple premise: if we present the right data, to the right audience ...

Thousands of people in England and Wales with a type of chronic heart failure (CHF) could soon be eligible for treatment with ...

The European Commission has approved Novo Nordisk's pill formulation of weight-loss therapy Wegovy, making it the first oral ...

After a delay, Eisai and Biogen have won FDA approval for their new subcutaneous formulation of Alzheimer's disease therapy ...

At the moment, many of the big AI systems used in drug discovery are closed-source, meaning they are proprietary and carry an ...